Jeeyun Lee

Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial

Evorpacept blocks the CD47–signal regulatory protein α interaction, enhancing antibody-dependent cellular phagocytosis. In the phase 2 portion of ASPEN-06 (a multicenter, open-label, randomized phase 2/3 study), 127 patients with pretreated, human epidermal growth factor receptor...

Real-world genomic landscape of FGFR2 amplifications and fusions in solid tumors: analysis of 4,953 patients using clinical-grade NGS

Fibroblast growth factor receptor 2 (FGFR2) alterations, including amplifications and fusions, are actionable oncogenic drivers in multiple cancers, but their prevalence and genomic features are not well defined. Between October 2019 and October 2024 at Samsung Medical Center, 4,...